Sol-Gel Technologies (NASDAQ:SLGL – Get Free Report) and Trulieve Cannabis (NYSE:TRLV – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.
Valuation & Earnings
This table compares Sol-Gel Technologies and Trulieve Cannabis”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sol-Gel Technologies | $19.39 million | 11.36 | -$6.13 million | ($5.64) | -11.95 |
| Trulieve Cannabis | $1.18 billion | 1.78 | -$116.38 million | $0.11 | 99.03 |
Sol-Gel Technologies has higher earnings, but lower revenue than Trulieve Cannabis. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Trulieve Cannabis, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current recommendations and price targets for Sol-Gel Technologies and Trulieve Cannabis, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sol-Gel Technologies | 1 | 0 | 4 | 2 | 3.00 |
| Trulieve Cannabis | 1 | 1 | 1 | 0 | 2.00 |
Sol-Gel Technologies currently has a consensus target price of $197.50, suggesting a potential upside of 193.07%. Trulieve Cannabis has a consensus target price of $15.00, suggesting a potential upside of 37.70%. Given Sol-Gel Technologies’ stronger consensus rating and higher possible upside, analysts plainly believe Sol-Gel Technologies is more favorable than Trulieve Cannabis.
Profitability
This table compares Sol-Gel Technologies and Trulieve Cannabis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sol-Gel Technologies | -910.14% | -44.05% | -36.96% |
| Trulieve Cannabis | -41.55% | -4.24% | -1.72% |
Institutional and Insider Ownership
26.2% of Sol-Gel Technologies shares are owned by institutional investors. 66.5% of Sol-Gel Technologies shares are owned by company insiders. Comparatively, 3.8% of Trulieve Cannabis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Sol-Gel Technologies beats Trulieve Cannabis on 8 of the 13 factors compared between the two stocks.
About Sol-Gel Technologies
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
About Trulieve Cannabis
Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, California, Massachusetts, Connecticut, Pennsylvania, and West Virginia, as well as directly to patients through home delivery. It produces approximately 550 stock keeping units, including flower, edibles, vaporizer cartridges, concentrates, topicals, capsules, tinctures, dissolvable powders, and nasal sprays. As of May 5, 2021, the company operated through 87 dispensaries in the United States. The company is headquartered in Quincy, Florida.
Receive News & Ratings for Sol-Gel Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sol-Gel Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
